Supernus Pharmaceuticals, Inc. (SUPN)Healthcare | Drug Manufacturers - Specialty & Generic | Rockville, United States | NasdaqGM
43.73 USD
-0.46
(-1.041%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 44.58 +0.85 (1.944%) ⇧ (Aug. 28, 2026, 7:51 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:43 a.m. EDT
The immediate narrative is one of aggressive speculation on a turnaround, but the underlying business remains fundamentally broken. While the stock has rallied nearly 100% over the last nine years, driven by a recent surge in revenue and a positive outlook for its CNS pipeline, the company is still bleeding cash with negative operating margins and negative earnings per share. The balance sheet is fragile, with debt-to-equity nearing 4x and free cash flow barely covering operations. The short-term rating is elevated to 3.5 because the recent price action shows strong momentum, and options flow suggests traders are betting on a continuation of this upside based on upcoming catalysts like the Qelbree anniversary and merger synergies. However, this is a high-risk momentum play, not a value recovery. The long-term rating holds at 3.0 because while the revenue growth is impressive, the lack of profitability and the precarious financial structure prevent it from being a 'buy and hold' candidate. There is no dividend to provide a floor, making the entire investment thesis dependent on the successful execution of its drug pipeline. Investors should view this as a speculative trade on the next quarter's results rather than a stable income or compounder vehicle. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.033994 |
| AutoTheta | 0.036546 |
| AutoARIMA | 0.046910 |
| MSTL | 0.053011 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 47% |
| H-stat | 1.88 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.833 |
| Excess Kurtosis | 0.32 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.895 |
| Revenue per Share | 14.465 |
| Market Cap | 2,541,894,144 |
| Forward P/E | 9.80 |
| Beta | 0.56 |
| Profit Margins | -13.23% |
| Website | https://www.supernus.com |
As of Aug. 22, 2026, 4:43 a.m. EDT: Speculators are positioning for a volatile rebound rather than a steady grind. In the near term (September/December 2026), there is heavy open interest in out-of-the-money calls at strikes significantly above the current price (55 and 60), suggesting bets on a sharp rally driven by pipeline news. However, deep out-of-the-money puts for late 2027 show massive open interest, indicating a hedge against a potential long-term failure or regulatory setback. The implied volatility skew is elevated, reflecting uncertainty about whether the recent price gains can sustain against the backdrop of negative earnings.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.018185914 |
| Address1 | 9,715 Key West Avenue |
| All Time High | 61.25 |
| All Time Low | 4.3 |
| Ask | 56.0 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Daily Volume10 Day | 576,590 |
| Average Daily Volume3 Month | 851,671 |
| Average Volume | 851,671 |
| Average Volume10Days | 576,590 |
| Beta | 0.56 |
| Bid | 33.83 |
| Bid Size | 2 |
| Board Risk | 3 |
| Book Value | 17.73 |
| City | Rockville |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 43.73 |
| Current Ratio | 2.083 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 44.3 |
| Day Low | 43.13 |
| Debt To Equity | 3.895 |
| Display Name | Supernus Pharmaceuticals |
| Earnings Call Timestamp End | 1,785,760,200 |
| Earnings Call Timestamp Start | 1,785,760,200 |
| Earnings Timestamp | 1,785,760,200 |
| Earnings Timestamp End | 1,793,709,000 |
| Earnings Timestamp Start | 1,793,709,000 |
| Ebitda | 110,432,000 |
| Ebitda Margins | 0.13298 |
| Enterprise To Ebitda | 20.012 |
| Enterprise To Revenue | 2.661 |
| Enterprise Value | 2,209,997,312 |
| Eps Current Year | 2.565 |
| Eps Forward | 4.46 |
| Eps Trailing Twelve Months | -1.9 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 46.7402 |
| Fifty Day Average Change | -3.0102005 |
| Fifty Day Average Change Percent | -0.06440282 |
| Fifty Two Week Change Percent | -1.8185914 |
| Fifty Two Week High | 59.68 |
| Fifty Two Week High Change | -15.950001 |
| Fifty Two Week High Change Percent | -0.26725873 |
| Fifty Two Week Low | 42.45 |
| Fifty Two Week Low Change | 1.2799988 |
| Fifty Two Week Low Change Percent | 0.030153092 |
| Fifty Two Week Range | 42.45 - 59.68 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,335,879,000,000 |
| Float Shares | 51,650,501 |
| Forward Eps | 4.46 |
| Forward P E | 9.804933 |
| Free Cashflow | 84,611,000 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 778 |
| Fullday Change | -0.459999 |
| Fullday Change Percent | -1.04096 |
| Fullday Price | 44.58 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.72890997 |
| Gross Profits | 605,312,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.044899996 |
| Held Percent Institutions | 1.06656 |
| Implied Shares Outstanding | 58,127,013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland. |
| Long Name | Supernus Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 2,541,894,144 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_422832 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -109,886,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,568,632,704 |
| Number Of Analyst Opinions | 4 |
| Open | 43.95 |
| Operating Cashflow | 19,911,000 |
| Operating Margins | -0.02485 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 301 838 2500 |
| Post Market Change | 0.8500023 |
| Post Market Change Percent | 1.943751 |
| Post Market Price | 44.58 |
| Post Market Time | 1,787,961,077 |
| Previous Close | 44.19 |
| Price Eps Current Year | 17.048733 |
| Price Hint | 2 |
| Price To Book | 2.4664412 |
| Price To Sales Trailing12 Months | 3.0609078 |
| Profit Margins | -0.13232 |
| Quick Ratio | 1.68 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.459999 |
| Regular Market Change Percent | -1.04096 |
| Regular Market Day High | 44.3 |
| Regular Market Day Low | 43.13 |
| Regular Market Day Range | 43.13 - 44.3 |
| Regular Market Open | 43.95 |
| Regular Market Previous Close | 44.19 |
| Regular Market Price | 43.73 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 487,775 |
| Return On Assets | 0.0038800002 |
| Return On Equity | -0.104899995 |
| Revenue Growth | 0.324 |
| Revenue Per Share | 14.465 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 58,127,013 |
| Shares Percent Shares Out | 0.0713 |
| Shares Short | 4,147,629 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,850,861 |
| Short Name | Supernus Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.0876 |
| Short Ratio | 4.42 |
| Source Interval | 15 |
| State | MD |
| Symbol | SUPN |
| Target High Price | 67.0 |
| Target Low Price | 55.0 |
| Target Mean Price | 61.75 |
| Target Median Price | 62.5 |
| Total Cash | 372,067,008 |
| Total Cash Per Share | 6.401 |
| Total Debt | 40,170,000 |
| Total Revenue | 830,438,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.9 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 48.53015 |
| Two Hundred Day Average Change | -4.800152 |
| Two Hundred Day Average Change Percent | -0.09891071 |
| Type Disp | Equity |
| Volume | 487,775 |
| Website | https://www.supernus.com |
| Zip | 20,850 |